Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
345
resultados
Última actualización
04/11/2026 [08:50:00]
Resultados 150 a 175 de 345
Resumen de: WO2026206998A1
Disclosed herein are methods and compositions for determining survival and treatment responsiveness of subjects with ovarian cancer. Specifically, the disclosure is directed to prognostic glucocorticoid receptor activity signatures for ovarian cancer. Also provided are methods for predicting responsiveness to certain cancer therapies (e.g., selective glucocorticoid receptor modulators (SGRMs)).
Resumen de: US20260297525A1
Disclosed herein are methods of expanding populations of patrolling monocytes in vitro and in vivo for treatment of sickle-cell disease (SCD), reducing pain and vaso-occlusive events in SCD patients, promoting wound healing, reducing tumor metastases, and treating vascular inflammatory conditions in subjects in need thereof.
Resumen de: US20260297180A1
0000 The present invention relates to the field of inflammation. More specifically, the present invention provides compositions and methods for treating diseases and conditions associated with the priming and activation of the NLR Family Pyrin Domain Containing 3 (NLRP3) inflammasome. In particular embodiments, the method comprises the step of administering to the patient an isolated, recombinant antibody or antigen-binding fragment thereof that binds human Resistin.
Resumen de: US20260298958A1
Disclosed is a specimen analysis method for analyzing a specimen regarding a plurality of measurement items, the specimen analysis method comprising: measuring a first measurement item and a second measurement item on the basis of a measurement order; executing a process related to a time difference between a measurement of the first measurement item and a measurement of the second measurement item; and obtaining a calculation value from a measurement value of the first measurement item and a measurement value of the second measurement item.
Resumen de: US20260298913A1
0000 The present disclosure relates to a method for detecting an analyte present in trace amounts in a fluid sample. The method includes at least: causing a fluid sample containing an analyte to flow over a substrate having an array of microchambers, with a first capture substance that specifically binds to the analyte immobilized in the microchambers; binding the analyte to the first capture substance; causing a second capture substance, which specifically binds to the analyte and binds to a signal-generating substance, to flow over the substrate; causing the signal-generating substance to flow over the substrate to bind to the second capture substance; causing a substrate solution to flow over the substrate; causing a hydrophobic solvent to flow over the substrate to remove the substrate solution present outside the microchambers; and counting and detecting the number of microchambers in which the fluorescence signal is generated.
Resumen de: AU2024347751A1
The present invention provides various biomarkers for identifying patients that are likely to benefit from treatment with a TLR inhibitor.
Resumen de: WO2025050066A1
The present disclosure provides compositions for activating TERT expression and methods of using the same for treating or ameliorating aging, aging-related diseases, and neurodegenerative conditions.
Resumen de: US20260294328A1
0000 Disclosed herein are methods for diagnosing Alzheimer's disease in a subject that involves administering to the subject an imaging agent comprising hyperpolarized pyruvate having a nuclear magnetic resonance (NMR)-detectable nucleus; applying radiation to the brain of the subject, wherein the radiation has a frequency that excites electron spin transitions in the DNP agent at an intensity to polarize the NMR-detectable nucleus; detecting magnetic resonance signals in the brain of the subject from nuclear spin transitions in the NMR-detectable nucleus to produce a spectrum measuring bicarbonate (Bic) and lactate (Lac) metabolites; and calculating a Bic/Lac ratio from the measured metabolites, wherein a reduced Bic/Lac ratio compared to control is an indication that the subject has Alzheimer's disease.
Resumen de: US20260298946A1
The invention relates to a method for selecting a patient suffering stroke for a reperfusion therapy based on determining the level of retinol binding protein-4 (RBP4) and N-terminal fragment of B-type natriuretic peptide (NT-proBNP) in an isolated sample of said patient. The invention also relates to a method of differentiating ischemic stroke from haemorrhagic stroke and to kits comprising reagents to carry out the methods.
Resumen de: US20260297486A1
0000 Disclosed herein are 3D culture systems and methods for producing epithelial tubular organoids, such as intestinal organoids. Also disclosed is a screening method that involves contacting elongated epithelial tubes produced from the disclosed systems and methods with a candidate agent, culturing the elongated epithelial tube in a growth medium under growth conditions, and evaluating the elongated epithelial tube for a physiological effect.
Resumen de: US20260294329A1
0000 A non-invasive device for detecting Alzheimer's Disease-associated pathologies, comprising a fundus camera comprising a spectral reflectance imaging unit that includes a broadband light source and a light sensor and a lens assembly to focus light from the broadband light source onto a fundus of an eye, and one or more processors to detect reflected and/or backscattered light from the eye, illuminated by the broadband light source, using the light sensor for determining spectral reflectance information, generate a plurality of spectral reflectance maps comprising counts of reflected and/or backscattered light at a different wavelength or a different range of wavelengths, assign a weight to each of the spectral reflectance maps, and determine one or more regions of interest from the weighted spectral reflectance maps as being a potential Alzheimer's Disease-associated pathology based on a detection of one or more biomarkers indicative of Tauopathy.
Resumen de: AU2025239644A1
Provided herein are medical uses of CD11a-enriched T regulatory cells for treating amyotrophic lateral sclerosis (ALS) or ameliorating a symptom of ALS. Such uses may include longitudinal analysis of biomarkers, such as inflammatory cytokines.
Resumen de: US20260298947A1
0000 A method for the in vitro diagnosis of a neurodegenerative disease, in a human or animal individual, at an early stage, including the step which includes in detecting the presence of at least one marker chosen from the derived forms of amyloid beta (Aβ) peptides selected from the oligomers of said peptides and the prefibrillar and fibrillar aggregated forms of said peptides, and the derived forms of phosphorylated tau proteins selected from the hyperphosphorylated forms of said proteins, the aggregated forms of said proteins and the modified phosphorylated tau proteins resulting from one or several post-translational modifications, the presence of the marker(s) being detected in a stool sample of said individual.
Resumen de: WO2026207251A1
The present disclosure provides systems, methods, compositions, and algorithms for treating a subject diagnosed with a glucose hypometabolic disorder (e.g., Alzheimer's disease, Parkinson's disease, or heart failure).
Resumen de: WO2026206859A1
Described herein are methods and kits for the early diagnosis of neurodegenerative diseases, such as Alzheimer's disease, by detecting the enzymatic activities of L1 variants. Increased levels of the enzymatic activities serve as biological indicators that can signal the presence or risk of developing such diseases, preceding the visible or detectable changes identified by conventional techniques. Also provided herein, are methods of treating neurodegenerative diseases following early diagnosis.
Resumen de: WO2026207302A1
Compositions, kits, systems, and methods for determining the presence and/or concentration of a phosphorylated Tau biomarker (such as, but not limited to, pTau217) in a biological sample and/or determining the presence of, severity of, and/or predisposition to Alzheimer's disease in an individual are disclosed. The compositions, kits, systems, and methods utilize at least two means for binding to Tau, including one means that is capable of distinguishing the phosphorylated Tau biomarker from unphosphorylated Tau, so that at least one sandwich complex can be formed. The methods include determining an amount of pTau present in the biological sample based on the amount of the sandwich immunocomplex formed.
Resumen de: WO2026202211A1
Methods of immunoassay are described for detecting in a patient sample (such as for example a blood, serum or plasma sample) a biomarker originating from α-Synuclein, and to the use of said methods of immunoassay for detecting and/or monitoring Parkinson's Disease or a level of severity thereof. Monoclonal antibodies and assay kits for use in said methods of immunoassay are also described.
Resumen de: WO2026205616A1
The present invention relates to an anti-APP antibody or an antigen-binding fragment thereof, and uses thereof. Specifically, the anti-APP antibody or antigen-binding fragment thereof according to the present invention may be utilized for analysis and detection of cell membrane APP, and further for diagnosis of APP-related diseases.
Resumen de: WO2026207317A1
A method for screening a subject in need thereof for amyotrophic lateral sclerosis (ALS) or slowing a progression of ALS, wherein the method includes measuring a level of at least a biomarker in the subject, such as without limitation by using a synthetic antibody, determining an ALS status indicator as a function of the measurement, and optionally providing a treatment to slow the progression of ALS as a function of the ALS status indicator, wherein the at least a biomarker includes a trimeric superoxide dismutase 1 (SOD1).
Resumen de: US20260298931A1
0000 A method for detecting colorectal cancer DNA using a lateral flow assay includes: extracting a blood sample (S100); loading the blood sample on a lateral flow assay (LFA) kit (S110); amplifying a specific target circulating tumor DNA (ctDNA) fragment using single nucleotide polymorphism (SNP) typing based on a loop-mediated isothermal amplification (LAMP) device on the kit (S130); allowing the amplified SNP sequence to move along a nitrocellulose membrane and binding to a gold nanoparticle probe to form a DNA-AuNP complex (S140); and color-developing a first probe to be visually detected in the complex forming process (S150), so as to detect whether colorectal cancer mutant DNA exists in the blood sample based on the color development.
Resumen de: WO2026206235A1
A mixing device for blending and measuring the thickness of fluids comprises a rotational motor with a motor shaft and a blade with a blade shaft. A torque sensor assembly connects the motor shaft to the blade shaft. The mixing motor operates in two modes. In mixing mode, the motor rotates in one direction at a high speed to mix and thicken fluids. In measuring mode, the motor rotates in the opposite direction at a low speed to assess the fluid's thickness. The rotation speed in this mode adapts to the thickness level of the fluid. A lift mechanism adjusts the height of a fluid container, allowing the blade to reach different depths for thorough mixing. Additionally, the device includes a powder container that dispenses a measured amount of thickening powder at the edge of the fluid container in a single release.
Resumen de: US20260298865A1
0000 A screen-printed sensor for detecting aluminum ions in food and biological samples is provided. The sensor includes an aluminum ion-selective membrane containing quercetin as an aluminum ionophore and multi-walled carbon nanotubes. The sensor provides a low-cost point of analysis method to determine aluminum ion concentration in a range of from 0.008 to 1070 μM in food and beverage materials, reflecting the general detection capability of the sensor under aqueous conditions.
Resumen de: WO2026199081A1
A multiplex biosensing device and system are disclosed, including a plurality of multiplex biosensing electrodes configured for simultaneous, real-time detection of multiple biomolecule markers. The multiplex biosensing electrodes may comprise working electrodes modified with diverse biosensing platforms. The biosensing platforms may include molecularly imprinted polymers, immunocomplex reactions, enzymatic reactions, or DNA hybridization, each customized to detect specific biomarkers. The device further includes a microfluidic delivery mechanism designed for the sequential processing and delivery of biofluid samples and reagents, using a separation or filter media to remove impurities. The multiplex biosensor system integrates the multiplex biosensing device and a detection apparatus may be wirelessly connected via Bluetooth or other communication modules, enabling remote, real-time data monitoring and analysis. The system supports various biofluids, including blood, plasma, urine, saliva, sputum, and sweat, facilitating diverse applications in health diagnostics, environmental monitoring, and food safety.
Resumen de: US20260298917A1
0000 This document relates to methods and materials for detecting the presence or absence of misfolded polypeptides in a sample. For example, a sample (e.g., a biological sample or an environmental sample) can be exposed to nanoparticles (e.g., nanoparticles having a size of no more than 2 μm (e.g., no more than 1 μm) such as silica nanoparticles (siNPs) having a size of no more than 2 μm (e.g., siNPs having a size of no more than 1 μm)) during a seeded amplification assay to accelerate the aggregation of misfolded polypeptides present in the sample into fibrils and/or polypeptide aggregates (e.g., globular polypeptide aggregates). In some cases, methods and materials provided herein can be used to determine if a mammal (e.g., a human) has a proteinopathy based, at least in part, in the presence or absence of misfolded polypeptides in a sample obtained from the mammal.
Nº publicación: KR20260143067A 30/09/2026
Solicitante:
UIF UNIV INDUSTRY FOUNDATION YONSEI UNIV [KR]
\uC5F0\uC138\uB300\uD559\uAD50 \uC0B0\uD559\uD611\uB825\uB2E8
Resumen de: KR20260143067A
본 발명은 퇴행성 뇌질환 치료제 스크리닝용 TDP-43 변이체에 관한 것으로, TDP-43의 특정 영역 돌연변이를 통해 병리적 응집체인 아밀로이드 섬유 형성을 안정적으로 유도함으로써 실제 퇴행성 뇌질환의 병리 현상을 정확히 모사하는 질환 모델을 제공할 수 있다. 또한, 1,6-hexanediol에 대한 저항성을 갖는 고체상의 응집체를 형성하여, 액상 응집체의 병리적 고체상 전이를 제어할 수 있는 치료제 후보 물질을 신속하고 효율적으로 선별할 수 있다. 또한, 효모 및 포유동물 세포 시스템을 이용한 다각적 스크리닝을 통해 약물의 효능 및 세포 독성을 동시에 평가할 수 있는 신뢰성 높은 약물 탐색 플랫폼으로 활용할 수 있다.
BOPI
Sede Electrónica
